FOLR1 and ovarian carcinoma: Mirvetuximab soravtansine’s ability to specifically target FRα-positive tumors establishes it as a promising treatment option for a biomarker-selected population, presenting a potential paradigm shift in managing platinum-resistant ovarian cancer.[18] In addition, exploring mirvetuximab soravtansine in combination with bevacizumab introduces a compelling dimension to treatment strategies.